NCI-MATCH arms fall short in ASCO abstracts

Three arms of NCI’s Molecular Analysis for Therapy Choice (NCI-MATCH) tissue agnostic basket trial will report overall response rates below 10% at this year’s American Society of Clinical Oncology meeting, according to abstracts released late Wednesday.

NCI-MATCH is a Phase II signal-seeking study that assigns patients with solid tumors, lymphomas or multiple myeloma to treatment arms according to molecular alterations in their cancers. According to NCI's website, treatments "will be considered promising if at least 16% of the patients in an arm have tumor shrinkage,” meaning a complete response (CR) or partial response (PR) to treatment...